financetom
Business
financetom
/
Business
/
Caribou Biosciences CFO Jason O'Byrne Resigns
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Caribou Biosciences CFO Jason O'Byrne Resigns
Sep 5, 2024 3:21 AM

05:55 PM EDT, 09/03/2024 (MT Newswires) -- Caribou Biosciences ( CRBU ) said Tuesday that Chief Financial Officer Jason O'Byrne is leaving the company on Sept. 27.

The company plans to appoint Ryan Fischesser, vice president of finance and control, as the principal accounting officer after Byrne leaves.

Caribou said it has initiated a search for new chief financial officer, according to a regulatory filing.

Shares were up more than 4% in recent after hours activity.

Price: 2.0700, Change: +0.09, Percent Change: +4.55

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Teva Pharmaceutical Industries Q3 Non-GAAP Earnings, Revenue Rise; Updates 2025 Guidance
Teva Pharmaceutical Industries Q3 Non-GAAP Earnings, Revenue Rise; Updates 2025 Guidance
Nov 5, 2025
07:38 AM EST, 11/05/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) reported Q3 non-GAAP earnings Wednesday of $0.78 per diluted share, up from $0.69 a year earlier. Analysts surveyed by FactSet expected $0.68. Net revenue for the quarter ended Sept. 30 was $4.48 billion, up from $4.33 billion a year earlier. Analysts surveyed by FactSet expected $4.34 billion....
Installed Building Products Q3 revenue up 2.3%, beats estimates
Installed Building Products Q3 revenue up 2.3%, beats estimates
Nov 5, 2025
Overview * Installed Building Products ( IBP ) Q3 revenue rose 2.3%, beating analyst expectations * Adjusted EBITDA for Q3 increased 5.7% to a record $139.9 mln * Company repurchased 200,000 shares for $51.5 mln in Q3 Outlook * Company anticipates some acquisition targets may be delayed to 2026 * IBP continues to prioritize growth through acquisitions * Company sees...
JLL Q3 revenue up 10%, beats expectations
JLL Q3 revenue up 10%, beats expectations
Nov 5, 2025
(Corrects company name in headline) Overview * JLL Q3 revenue grows 10% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, rising 29% yr/yr * Company repurchased $70 mln in shares this quarter, up 118% yr/yr Outlook * JLL raises mid-point of full-year Adjusted EBITDA target * Company expects continued momentum into the fourth quarter * JLL sees...
Minerva Neurosciences reports $2.7 mln Q3 net loss
Minerva Neurosciences reports $2.7 mln Q3 net loss
Nov 5, 2025
Overview * Minerva reports Q3 net loss of $2.7 mln, contrasting with net income in Q3 2024 * Company's Q3 operating expenses decreased due to lower R&D and G&A costs * Minerva secures $80 mln in financing for Phase 3 trial of roluperidone Outlook * Minerva anticipates increased R&D and administrative expenses for Phase 3 trial and NDA resubmission *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved